

## Vitamin D, the placenta and early pregnancy

Ganguly, Ankana; Tamblyn, Jennifer Ann; Finn-Sell, Sarah; Chan, Shiao-Yng; Westwood, Melissa; Gupta, Janesh; Kilby, Mark; Gross, Stephane R; Hewison, Martin

DOI:

[10.1530/JOE-17-0491](https://doi.org/10.1530/JOE-17-0491)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Ganguly, A, Tamblyn, JA, Finn-Sell, S, Chan, S-Y, Westwood, M, Gupta, J, Kilby, M, Gross, SR & Hewison, M 2017, 'Vitamin D, the placenta and early pregnancy: effects on trophoblast function', *Journal of Endocrinology*. <https://doi.org/10.1530/JOE-17-0491>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Checked for eligibility: 19/12/2017

Disclaimer: this is not the definitive version of record of this article. This manuscript has been accepted for publication in Journal of Endocrinology, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no responsibility for any errors or omissions it may contain. The definitive version is now freely available at 10.1530/JOE-17-0491 2017

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1 **Vitamin D, the placenta and early pregnancy: effects on trophoblast**  
2 **function**

3  
4 Ankana Ganguly<sup>1</sup> Jennifer A. Tamblyn<sup>1,2,3</sup>, Sarah Finn-Sell<sup>4</sup>, Shiao-Y Chan<sup>5</sup>, Melissa  
5 Westwood<sup>4</sup>, Janesh Gupta<sup>1,2</sup>, Mark D. Kilby<sup>1,2</sup>, Stephane R. Gross<sup>6</sup>, Martin Hewison<sup>1,3</sup>

6  
7 <sup>1</sup>Institute of Metabolism and Systems Research, the University of Birmingham, Birmingham  
8 B15 2TT, UK

9 <sup>2</sup>Fetal Medicine Centre, Birmingham Women's NHS Foundation Trust, Birmingham B15 2TT,  
10 UK

11 <sup>3</sup>CEDAM, Birmingham Health Partners, the University of Birmingham, Birmingham B15 2TT,  
12 UK

13 <sup>4</sup>Maternal and Fetal Health Research Centre, Division of Developmental Biology and  
14 Medicine, School of Medicine, Faculty of Biology, Medicine and Health, University of  
15 Manchester, Manchester Academic Health Science Centre, M13 9PL, UK

16 <sup>5</sup>Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National  
17 University of Singapore, 119228, Singapore.

18 <sup>6</sup>School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK

19  
20 \* Corresponding author:

21 Martin Hewison PhD  
22 Institute of Metabolism & Systems Research  
23 Level 2, IBR, Rm 225  
24 The University of Birmingham  
25 Birmingham, B15 2TT  
26 UK

27 email: [m.hewison@bham.ac.uk](mailto:m.hewison@bham.ac.uk)

28 Tel: +44 (0)121 414 6908

29 Fax: +44 (0) 121 415 8712

30  
31 Short title: Vitamin D and trophoblast function

32 Key words: vitamin D, pregnancy, placenta, trophoblast, miscarriage

33

## 34     **Abstract**

35     Pregnancy is associated with significant changes in vitamin D metabolism, notably increased  
36     maternal serum levels of active vitamin D, 1,25-dihydroxyvitamin ( $1,25(\text{OH})_2\text{D}$ ). This appears  
37     to be due primarily to increased renal activity of the enzyme 25-hydroxyvitamin D-1 $\alpha$ -  
38     hydroxylase (CYP27B1) that catalyzes synthesis of  $1,25(\text{OH})_2\text{D}$ , but CYP27B1 expression is  
39     also prominent in both the maternal decidua and fetal trophoblast components of the  
40     placenta. The precise function of placental synthesis of  $1,25(\text{OH})_2\text{D}$  remains unclear, but is  
41     likely to involve localised tissue-specific responses with both decidua and trophoblast also  
42     expressing the vitamin D receptor (VDR) for  $1,25(\text{OH})_2\text{D}$ . We have previously described  
43     immunomodulatory responses to  $1,25(\text{OH})_2\text{D}$  by diverse populations of VDR-expressing  
44     cells within the decidua. The aim of the current review is to detail the role of vitamin D in  
45     pregnancy from a trophoblast perspective, with particular emphasis on the potential role of  
46      $1,25(\text{OH})_2\text{D}$  as a regulator of trophoblast invasion in early pregnancy. Vitamin D-deficiency is  
47     common in pregnant women, and a wide range of studies have linked low vitamin D status to  
48     adverse events in pregnancy. To date most of these studies have focused on adverse  
49     events later in pregnancy, but the current review will explore the potential impact of vitamin  
50     D on early pregnancy, and how this may influence implantation and miscarriage.

51

52

53

54

55

56

57

58     **Introduction**

59     The human placenta is a vital organ without which the mammalian fetus cannot survive. It  
60     forms the interface between the mother and fetus, supplying the fetus with oxygen, nutrients,  
61     excreting waste products, whilst protecting against maternal immunologic attack. The main  
62     functions of the placenta can be broadly categorised into transport and metabolism,  
63     protection and endocrine (Gude, et al. 2004). The complex architecture of the placenta,  
64     bounded by the maternal aspect (basal plate) and the fetal aspect (chorionic plate), houses  
65     an abundance of the fundamental functional unit of the placenta, the chorionic villus, where  
66     all nutritional-waste exchange between the maternal blood and the fetal circulation occurs.  
67     As well as facilitating a good maternal blood supply for nutrition-waste exchange, and  
68     orchestrating endocrine mediators of pregnancy to maintain maternal physiological changes  
69     for an optimal environment for fetal development, the placenta also acts to protect the fetus  
70     from xenobiotic materials and infectious agents (Gude et al. 2004; Moore, et al. 1999;  
71     Rudge, et al. 2009; Yang 1997). Successful development of the placenta involves two  
72     distinct mechanisms: implantation of the blastocyst, initiated by attachment of the embryo to  
73     the maternal endometrial epithelium, and invasion of fetal trophoblast cells into the maternal  
74     endometrium to facilitate maternal-fetal exchange of nutrients, gases and waste. The diverse  
75     mechanisms associated with the regulation of trophoblast invasion have been well  
76     documented (Menkhorst, et al. 2016). The aim of the current review is to provide an  
77     overview of these early events in placental development, with particular emphasis on the  
78     potential role of vitamin D as a determinant of early placental development through effects  
79     on trophoblast cells, particularly via effects of vitamin D on trophoblast invasion.

80

81     **Vitamin D and pregnancy**

82     Despite its long-standing association with rickets and osteoporosis, vitamin D has become  
83     increasingly recognized as a pluripotent regulator of biological functions above and beyond  
84     its classical effects on bone and calcium homeostasis. Expression of vitamin D receptor

(VDR) for the active form of vitamin D, 1,25-dihydroxyvitamin D ( $1,25(\text{OH})_2\text{D}$ ), as well as the  $1\alpha$ -hydroxylase enzyme that synthesizes  $1,25(\text{OH})_2\text{D}$  (CYP27B1), has been reported for various tissues that can be broadly termed 'barrier sites' (Jones, et al. 1998; Townsend, et al. 2005), indicating that localized responses to vitamin D may be a key feature of these tissues. Prominent amongst these barrier sites is the placenta, acting as the interface between mother and fetus. Historically, the placenta was one of the first extra-renal tissues shown to be capable of synthesizing  $1,25(\text{OH})_2\text{D}$ , with CYP27B1 activity detectable in both maternal decidua and fetal trophoblast (Gray, et al. 1979; Weisman, et al. 1979). Initially, this was linked to the rise in maternal serum  $1,25(\text{OH})_2\text{D}$  that occurs at the end of the first trimester of pregnancy. However, studies of CYP27B1-deficient animals and an anephric pregnant woman indicated that this is not likely to be the case (Kovacs and Kronenberg 1997). Instead, the presence of VDR in the placenta suggests that vitamin D functions in tissue-specific fashion at the fetal-maternal interface (Bruns and Bruns 1983). One possible explanation is that  $1,25(\text{OH})_2\text{D}$  acts as a regulator of placental calcium transport (Bruns and Bruns 1983), but a placental immunomodulatory function has also been proposed (Liu and Hewison 2012). Moreover, the rapid induction of VDR and CYP27B1 early in pregnancy (Zehnder, et al. 2002) suggests that vitamin D may play a more fundamental role in the process of conception, implantation and development of the placenta itself.

## **Vitamin D and implantation**

To date the precise role of vitamin D in the process of implantation remains unclear. Nevertheless, vitamin D has a biologically plausible role in female reproduction and implantation process.  $1,25(\text{OH})_2\text{D}$  has been shown to regulate expression of the homeobox gene HOXA10 in human endometrial stromal cells (Du, et al. 2005b). HOXA10 is important for the development of the uterus during fetal life and, later in adulthood, is essential for endometrial development, allowing uterine receptivity to implantation (Bagot, et al. 2000). Interestingly, animal studies have shown that vitamin D-deficiency reduces mating success

and fertility in female rats. Female rats fed with a vitamin D-deficient diet are capable of reproduction, but overall fertility is reduced including the failure of implantation (Halloran and DeLuca 1980). This was shown to be corrected by administration of  $1,25(\text{OH})_2\text{D}$  (Kwiecinski, et al. 1989), but also by use of diets high in calcium, phosphate and lactose (Johnson and DeLuca 2002), suggesting that the fertility effects of vitamin D may be due to indirect effects on mineral homeostasis. Other studies using knockout mouse models have further highlighted the importance of the vitamin D metabolic and signalling system in the process of implantation, with *Vdr*  $-/-$  and *Cyp27b1*  $-/-$  female mice both presenting with uterine hypoplasia and infertility (Panda, et al. 2001; Yoshizawa, et al. 1997). Conversely, injection of  $1,25(\text{OH})_2\text{D}$  has been shown to increase uterine weight and promote endometrial to decidual differentiation (Halhali, et al. 1991).

As well as regulating uterine and decidual development, vitamin D may also influence implantation indirectly via its well-known immunomodulatory actions. Regulation of immune function at the maternal-fetal interface involves a heterogeneous population of innate and adaptive immune cell subsets. Thus throughout pregnancy, decidual synthesis of  $1,25(\text{OH})_2\text{D}$  has the potential to influence uterine natural killer cells, dendritic cells, macrophages, and T-cells (Evans, et al. 2004; Tamblyn, et al. 2015). Notable effects include inhibition of Th1 cytokines and promotion of Th2 cytokines (Gregori, et al. 2001), which are known to play a significant role in the process of implantation (Piccinni, et al. 2000; Zehnder et al. 2002). Purification of decidual cells into non-adherent stromal cells and adherent cells, which include decidual macrophages and uterine natural killer cells, has shown that adherent cells demonstrate a greater capacity for  $1,25(\text{OH})_2\text{D}$  production (Kachkache, et al. 1993). Furthermore, first-trimester decidual cells treated with either  $25\text{OHD}$ - or  $1,25(\text{OH})_2\text{D}$  demonstrate significant induction of antibacterial protein cathelicidin and  $\beta$ -defensins (Evans, et al. 2006; Liu, et al. 2009). Since similar effects of vitamin D are observed in peripheral monocytes, an equivalent innate antimicrobial responsivity is postulated to exist at the maternal-fetal interface (Liu and Hewison 2012).

## Vitamin D metabolism and function in trophoblast cells

The organisation of maternal and fetal cells within the developing placenta has been well documented elsewhere (Oreshkova, et al. 2012; Vigano, et al. 2003), and is represented schematically in **Figure 1**. Both the maternal decidua and fetal trophoblast components of the placenta (including syncytiotrophoblast and invasive extravillous trophoblast [EVT]) express CYP27B1 (Zehnder et al. 2002), and are able to produce detectable levels of 1,25(OH)<sub>2</sub>D (Gray et al. 1979; Weisman et al. 1979). The resulting tissue concentrations of 1,25(OH)<sub>2</sub>D appear to be significantly higher in the decidua (Tamblyn, et al. 2017), but the coincident expression of VDR in trophoblast as well as decidua (Evans et al. 2004) means that multiple cell types within the placenta are capable of responding to the locally synthesized 1,25(OH)<sub>2</sub>D, either in an autocrine or paracrine fashion.

To date, studies of the physiological impact of decidual-trophoblast 1,25(OH)<sub>2</sub>D production have focused primarily on trophoblast cells, using both primary cultures of EVT and trophoblast cells lines. Primary cultures of human syncytiotrophoblast express CYP27B1 and are able to synthesize 1,25(OH)<sub>2</sub>D (Diaz, et al. 2000), and also express VDR (Pospechova, et al. 2009). However, in choriocarcinoma trophoblast cell lines such as BeWo and JEG-3, expression of VDR is low, with analysis of the effects of chromatin remodelling agents suggesting that this may be due to epigenetic suppression of VDR in these cells (Pospechova et al. 2009). Further studies to assess the impact of differentiation of cultured trophoblast cells have been carried out using cyclic AMP (cAMP) to mimic the process of syncytialisation (Keryer, et al. 1998). Expression of hCG is elevated by cAMP in trophoblast cells, and this was associated with decreased expression of CYP27B1, with VDR expression being unaffected (Avila, et al. 2007), suggesting that presence of the vitamin D metabolic and signalling pathways in the placenta is differentiation-sensitive. The JEG-3 trophoblast cell line has also been reported to express CYP27B1, but synthesis of 1,25(OH)<sub>2</sub>D by these

cells appears to be significantly less than observed with primary trophoblast cells and unaffected by cAMP (Pospechova et al. 2009). In addition to cAMP, inflammatory cytokines (Noyola-Martinez, et al. 2014), and insulin-like growth factor I (Halhali, et al. 1999) also stimulate trophoblast expression of CYP27B1 and synthesis of 1,25(OH)<sub>2</sub>D.

The vitamin D catabolic enzyme CYP24A1 has been reported to be undetectable in trophoblast cells, consistent with methylation epigenetic silencing of this gene in the human placenta (Novakovic, et al. 2009). This suggests that synthesis of 1,25(OH)<sub>2</sub>D by trophoblast cells is not subject to the same catabolic feedback control observed in other VDR-expressing tissues. However, other studies have shown that trophoblast expression of CYP24A1 is increased following treatment with cAMP (Avila et al. 2007). In addition, studies using the *Hyp* mouse model, which has elevated circulating levels of the positive regulator of 24-hydroxylase fibroblast growth factor 23 (FGF23), showed elevated placental expression of CYP24A1 mRNA in these mice (Ma, et al. 2014; Ohata, et al. 2014). Likewise, direct injection of FGF23 into normal placentas from wild type mice also induced expression of CYP24A1 (Ohata et al. 2014). This appears to be mediated via trophoblast expression of fibroblast growth factor receptor 1 and its co-receptor  $\alpha$ -klotho by trophoblast, suggesting that catabolism via CYP24A1 plays an as yet undefined role in mediating trophoblast effects of vitamin D.

Despite a wide range of studies showing regulation and activity of vitamin D metabolic enzymes in primary trophoblast cells and trophoblast cell lines, the principal functional analysis of vitamin D in these cells has centered on responses to 1,25(OH)<sub>2</sub>D. Initial experiments using JEG-3 cells described stimulation of calcium uptake (Tuan, et al. 1991), and the regulation of the cytosolic calcium binding protein calbindin-D28K (Belkacemi, et al. 2005) by 1,25(OH)<sub>2</sub>D, consistent with a role for vitamin D in the endocrinology of placental calcium homeostasis. However, subsequent investigations of trophoblast cells and 1,25(OH)<sub>2</sub>D have explored other mechanisms associated with placental endocrine function.



These reports include the stimulation of human placental lactogen synthesis and release (Stephanou, et al. 1994), hCG expression (Barrera, et al. 2008), and the regulation of estradiol and progesterone synthesis (Barrera, et al. 2007).

In recent years, our perspective on vitamin D and trophoblast function has been expanded to include studies of immunomodulatory function. In primary trophoblast cells and trophoblast cell lines,  $1,25(\text{OH})_2\text{D}$  has been shown to potently stimulate expression of the antibacterial protein cathelicidin (Liu et al. 2009), whilst also suppressing inflammatory responses to tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) (Diaz, et al. 2009). Similar anti-inflammatory responses to  $1,25(\text{OH})_2\text{D}$  have also been reported using trophoblasts from women with the inflammatory disorders of pregnancy, preeclampsia (Noyola-Martinez, et al. 2013), and antiphospholipid syndrome (APS) (Gysler, et al. 2015). In recent studies the anti-inflammatory effects of  $1,25(\text{OH})_2\text{D}$  on trophoblasts have been reported to include attenuation of oxidative stress-induced microparticle release from preeclampsia trophoblastic cells (Xu, et al. 2017), further underlining the importance of this facet of vitamin D function within the placenta. *In vivo*, studies using *Cyp27b1*<sup>-/-</sup> and *Vdr*<sup>-/-</sup> mice have shown that loss of both alleles for either of these genes on the fetal side of the placenta alone was sufficient to dramatically exacerbate anti-inflammatory responses to lipopolysaccharide (LPS) immune challenge (Liu, et al. 2011). Thus, in addition to the active immune cell function classically observed in the maternal decidua, trophoblast cells also appear to make a major contribution to the regulation of placental inflammation.

### **A role for vitamin D in EVT invasion?**

Controlled invasion of fetal cytotrophoblast and differentiated EVT cells into the maternal decidua and myometrium in the first trimester of pregnancy is a key process in placentation, and is essential for successful pregnancy. A complex network of communications among trophoblast, decidual stromal, and immune cells is reported to facilitate implantation and

maintenance of pregnancy, with key roles in tissue remodelling, cell trafficking, and immune tolerance being evident (Oreshkova et al. 2012). The mechanisms underpinning these processes have received increasing attention since abnormal placentation due to shallow invasion of EVT can cause important pregnancy disorders such as miscarriage (Ball, et al. 2006), pre-eclampsia (Caniggia, et al. 2000), fetal growth restriction, pre-term birth, and stillbirth (Reddy, et al. 2006) (Goldman-Wohl and Yagel 2002; Kadyrov, et al. 2006; Kaufmann, et al. 2003). By contrast, unrestricted invasion resulting from a failure to restrain the invading cytotrophoblast is associated with premalignant conditions such as malignant choriocarcinomas and invasive mole (Caniggia et al. 2000; Ringertz 1970), and can lead to aberrant placentation such as pathological adhesion to the myometrium (placenta accreta), extension into the myometrium (placenta increta), or invasion through the myometrium into adjacent organs (placenta percreta) (Khong 2008).

In recent studies we have shown that human EVT isolated from first trimester pregnancies are a target for both 25(OH)D and 1,25(OH)<sub>2</sub>D (Chan, et al. 2015). In *ex vivo* experiments both vitamin D metabolites promoted the invasion of EVT through Matrigel, with zymographic analysis showing that this effect involves enhanced expression of the matrix metalloproteinases pro-MMP2 and pro-MMP9 (Chan et al. 2015). These observations are in direct contrast to previously published studies describing 1,25(OH)<sub>2</sub>D inhibition of matrix invasion by tumor cells (Bao, et al. 2006). In this case the primary mode of action for 1,25(OH)<sub>2</sub>D was indirect suppression of MMPs via enhanced tissue inhibitor of metalloproteinase-1 (TIMP-1) expression. However, in other reports, low vitamin D status has been shown to be associated with elevated circulating MMP2 and MMP9 (Timms, et al. 2002). Suppression of a variety of MMPs, including MMP2 and MMP9, by 1,25(OH)<sub>2</sub>D has also been described for primary cultures of human uterine fibroid cells and uterine fibroid cell lines (Halder, et al. 2013). Thus, the pro-invasive effects of vitamin D on EVTs appear to be quite distinct to pregnancy and the placenta.

249

250 The concept of vitamin D as a regulator of cellular motility and invasion is not novel and has  
 251 been extensively reported in cancer states (Krishnan, et al. 2012; Leyssens, et al. 2014; Ma,  
 252 et al. 2016), where effects of vitamin D have been related to modulation of epithelial  
 253 mesenchymal transition (EMT) (Chen, et al. 2015; Fischer and Agrawal 2014; Hou, et al.  
 254 2016). Interestingly, this effect of vitamin D has not been observed in non-pathophysiological  
 255 states or during embryogenesis. For example, vitamin D is known to inhibit invasion and  
 256 motility of ovarian cancer and teratocarcinoma cell lines, but does not affect these cellular  
 257 characteristics in the non-neoplastic ESD3 murine embryonic cell line (Abdelbaset-Ismail, et  
 258 al. 2016). The precise molecular mechanisms that mediate migration and invasion regulation  
 259 by vitamin D remain unclear, although several different pathways have been studied.  
 260 Notably, vitamin D has been shown to regulate the actin cytoskeleton in numerous cell  
 261 types. In osteoblast-like cells, vitamin D promotes actin polymerisation as part of its  
 262 transcriptional induction of fibroblast growth factor 23 (Fajol, et al. 2016). In endometrial  
 263 cells, vitamin D treatment has also been shown to induce changes in actin architecture,  
 264 through regulation of the RAc1/Pak1 axis (Zeng, et al. 2016). It is not clear if such responses  
 265 are also seen in trophoblast cells during placental development, but vitamin D has been  
 266 shown to rescue motility defects in fetal endothelial colony forming cell function of umbilical  
 267 vein endothelial cells derived from pregnancies complicated by preeclampsia (von Versen-  
 268 Hoynck, et al. 2014) and gestational diabetes (Gui, et al. 2015).

269

270 Effects of vitamin D on EVT invasion and migration may also be mediated indirectly via  
 271 effects on other known EVT regulators.  $1,25(\text{OH})_2\text{D}$  has been shown to abolish S1P  
 272 mediated inhibition of migration via suppression of S1PR2 in trophoblast cell lines Swan-71  
 273 and JEG-3 (Westwood 2017).  $1,25(\text{OH})_2\text{D}$  has also been shown to stimulate  
 274 hCG expression and secretion via a cAMP/PKA-mediated signalling pathway (Barrera et al.  
 275 2008). Although hCG is a potent regulator of trophoblast motility and invasion (Chen, et al.  
 276 2011; Evans 2016), it is unclear whether changes in hCG expression are specifically

required for effects of vitamin D on trophoblast invasion. In a similar fashion,  $1,25(\text{OH})_2\text{D}_3$  has been shown to positively regulate progesterone synthesis by human trophoblast cells from term placenta (Barrera et al. 2007). In HTR8/SVneo trophoblast cells, which have been reported to consist of a mixed population of cells, progesterone appears to suppress trophoblast motility and invasion (Chen et al. 2011). Thus,  $1,25(\text{OH})_2\text{D}$  may exert indirect effects on trophoblast invasion, although it is still not clear whether these effects are pro-migratory. Indirect actions of vitamin D on EVT function may also stem from effects on placental cell differentiation. Recent studies have shown that inactivation of VDR in trophoblastic BeWo cells resulted in increased trophoblast differentiation and syncytium formation (Nguyen, et al. 2015). In a similar fashion vitamin D may also influence EVT invasion and motility indirectly by targeting the development of cells on the maternal side of the placenta. Endometrial stromal cells treated with  $1,25(\text{OH})_2\text{D}$  have elevated expression of specific genes, including HOXA10 (Du, et al. 2005a), which are known to be involved in the regional development of uterine decidualization and embryo implantation by controlling downstream target genes. The complex circuitry of vitamin D metabolism and function involved in mediating direct or indirect effects on EVT invasion and migration has still to be fully elucidated and is likely to be a key component of future studies of vitamin D in pregnancy.

**Vitamin D and trophoblast function: clinical implications**

Irrespective of proposed functional targets, vitamin D-dysregulation during pregnancy has been linked to adverse effects on placental function and pregnancy in general. In 2010 the Institute of Medicine (IOM) defined vitamin deficiency as serum concentrations of  $25(\text{OH})\text{D}$  less than 20 ng/ml (50 nM) (Holick, et al. 2011a). Subsequently the Endocrine Society issued slightly different guidelines, defining vitamin D-insufficiency as being serum  $25(\text{OH})\text{D}$  levels below 30 ng/ml (75 nM) (Holick, et al. 2011b). Against this backdrop, several recent publications have highlighted the prevalence of low serum concentrations of  $25(\text{OH})\text{D}$  (less

than 25 nM) in pregnant women: 20% of pregnant women in the UK (Javaid, et al. 2006), 25% in the UAE (Dawodu, et al. 1997), 80% in Iran (Bassir, et al. 2001), 45% in northern India (Sachan, et al. 2005), 60% in New Zealand (Eagleton and Judkins 2006) and 60–84% of pregnant non-Western women in the Netherlands (van der Meer, et al. 2006). It remains unclear if this reflects simply a normal physiological drop in vitamin D concentrations during pregnancy or if pregnancy is a stress test which can exacerbate and unmask pathological vitamin D deficiency.

Vitamin D deficiency in pregnant women has been shown to be associated with increased risk for pregnancy complications (Lewis, et al. 2010). These include preeclampsia (Bodnar, et al. 2007b), fetal growth restriction, small for gestational age fetus (Bodnar, et al. 2010), bacterial vaginosis (Bodnar, et al. 2009), and gestational diabetes mellitus (Maghbooli, et al. 2008; Zhang, et al. 2008). Maternal vitamin D-deficiency has also been linked to adverse effects in offspring, including reduced bone density (Javaid et al. 2006) and childhood rickets (Wagner and Greer 2008), as well as increased risk of asthma (Camargo, et al. 2007), and schizophrenia (McGrath 2001).

The impact of vitamin D status on early events in pregnancy has also been studied. In northern countries, where there is a strong seasonal contrast in light exposure and UVB-induced vitamin D production in skin, conception rates are decreased during winter months, with rates rising during summer and an increased birth rate in spring (Rojansky, et al. 1992). Interestingly, ovulation rates and endometrial receptivity also appear to be reduced during long dark winters in northern countries (Rojansky, et al. 2000), which may be explained in part by seasonal variations in vitamin D levels. With this in mind, several observational studies have investigated the potential impact of vitamin D on *in vitro* fertilisation (IVF), albeit with largely conflicting outcomes. In a study of infertile women undergoing IVF, those with higher levels of 25(OH)D in serum and follicular fluid, were more likely to achieve pregnancy following IVF, and high vitamin D levels were also shown to improve the parameters of

controlled ovarian hyperstimulation (Ozkan, et al. 2010). Aleyasin et al. found no significant association between 25(OH)D levels in serum and follicular fluid with IVF outcomes (Aleyasin, et al. 2011). However, this did not include any women with a serum vitamin D level >50nmol/L. In another study of 100 women undergoing IVF, serum concentrations of 25(OH)D were positively associated with fertilization rate (Abadia, et al. 2016). However, serum 25(OH)D was unrelated to the probability of pregnancy or live birth after IVF (Abadia et al. 2016). Anifandis et al. investigated 101 women who received IVF-intracytoplasmic sperm injection (ICSI) ovarian stimulation cycles. In this study, women with vitamin D-sufficiency (25(OH)D level >30 ng/ml in follicular fluid) had a lower quality of embryos and were less likely to achieve clinical pregnancy, compared with women with insufficient (follicular fluid 25(OH)D level 20.10 to 30 ng/ml) or deficient vitamin D status (follicular fluid 25(OH)D level <20 ng/ml) (Anifandis, et al. 2010).

Elucidation of the immunomodulatory effects of 1,25(OH)<sub>2</sub>D has led to the suggestion that vitamin D might have a role in protecting against spontaneous abortion (Bubanovic 2004). This was supported by *ex vivo* analyses showing that 1,25(OH)<sub>2</sub>D is able to suppress inflammatory cytokine production by endometrial cells from women with unexplained recurrent spontaneous abortions (Tavakoli, et al. 2011). More recently, 1,25(OH)<sub>2</sub>D has been shown to potently regulate natural killer cells from women with recurrent miscarriage (Ota, et al. 2015). Considering these observations, the impact of maternal vitamin D status on pregnancy outcome has been studied in several cohorts. In a large prospective cohort study of 1683 pregnant women donating serum before gestational week 22, serum concentrations of 25(OH)D less than 50 nM were associated with a >2-fold increase in first miscarriage rate, although no significant effect was observed for second trimester miscarriage (Andersen, et al. 2015). In a prospective study of pre-conceptual vitamin D, maternal serum 25(OH)D levels were not found to be associated with chances of conceiving or overall risk of miscarriage (Moller, et al. 2012). However, women with miscarriage in the second trimester had lower first trimester serum concentrations of 25(OH)D than those

women who did not miscarry (Moller et al. 2012). In a much larger, nested case-control study of over 5,000 women did not reveal any adverse effects of low serum 25(OH)D on pregnancy outcomes (Schneuer, et al. 2014). A recent meta-analysis and systematic review concluded that vitamin D-deficiency is not associated with increased risk of spontaneous recurrent abortion (Amegah, et al. 2017). Thus, the possible impact of sub-optimal vitamin D on implantation and adverse pregnancy outcomes such as miscarriage still remains unclear. Interestingly, in endometrial tissue from women with unexplained recurrent spontaneous abortion, expression of key components in the vitamin D metabolic (CYP27B1/CYP24A1) and signalling (VDR) systems was found to be comparable to endometrial tissue from healthy fertile women (Tavakoli, et al. 2015). By contrast, recent studies of women with recurrent miscarriage showed that expression of mRNA and protein for CYP27B1 in villous and decidual tissue was lower than in control tissues from normal healthy pregnancies (Wang, et al. 2016). In future studies it will be important to clarify how variations in the vitamin D system within the placenta and fetal trophoblast cells affect implantation and the maintenance of a successful healthy pregnancy.

A major contributing factor to vitamin D status in pregnant women is obesity, with lower circulating levels of 25(OH)D being reported in pregnant women with high body mass index (BMI), relative to pregnant women with a normal BMI (Bodnar, et al. 2007a; Karlsson, et al. 2015). Maternal obesity is associated with adverse health effects for both mother and child, with increased inflammation has been proposed as an important pathological mechanism for the detrimental effects of obesity during pregnancy (Denison, et al. 2010; Pantham, et al. 2015). A role of vitamin D in the process is still unclear. However, given the established anti-inflammatory effects of vitamin D at the fetal-maternal interface (Tamblyn et al. 2015) it is possible that some pregnancy effects of obesity are mediated via low circulating maternal vitamin D.

**Conclusions**

Expression of placental CYP27B1 and VDR at early stages of pregnancy suggests an important role for vitamin D in placental physiology. In previous studies we have hypothesized that placental vitamin D may function, at least in part, to promote anti-microbial and anti-inflammatory immune activity, with both the maternal decidua and fetal trophoblast contributing to these actions. However, analysis of trophoblast cells *ex vivo* and *in vitro* indicates that vitamin D may have a much broader role in placental function, including the regulation of trophoblast differentiation and EVT invasion of the decidua and myometrium (**Figure 1**). Thus, effects of vitamin D may occur earlier in pregnancy than previously appreciated, underlining the requirement for adequate vitamin D status across gestation. To date, studies of vitamin D status (maternal serum 25(OH)D) in pregnancy have tended to focus on later stages of pregnancy, and associated adverse events such as preterm birth, gestational diabetes and preeclampsia. Likewise, supplementation trials for vitamin D in pregnancy have focused on women between 10 and 18 weeks of pregnancy. However, the responsiveness of trophoblast cells to 1,25(OH)<sub>2</sub>D, notably effects on EVT invasion, suggests that further studies of vitamin D and adverse events in early pregnancy are required. To date there have been a limited number of reports of vitamin D-deficiency and miscarriage, but these need to be expanded to include more rigorous supplementation trials. The review we present is supportive of early, pre-conceptual, supplementation with vitamin D.

**Acknowledgements**

This study was supported by funding from Action Medical Research (#1949 to MK & MH), and Wellbeing of Women (RTF401, JAT), Medical Research Council grant MR/M02296X/1 (MW & SF-S), and a Royal Society Wolfson Merit Award (WM130118 to MH).



411    **Declaration of Interests**

412    The authors declare that there is no conflict of interest that could be prejudicing  
413    the impartiality of the research reported.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437 **References**

- 438 Abadia L, Gaskins AJ, Chiu YH, Williams PL, Keller M, Wright DL, Souter I, Hauser R,  
439 Chavarro JE, Environment, et al. 2016 Serum 25-hydroxyvitamin D concentrations and  
440 treatment outcomes of women undergoing assisted reproduction. *Am J Clin Nutr* **104** 729-  
441 735.
- 442 Abdelbaset-Ismail A, Pedziwiatr D, Suszynska E, Sluczanowska-Glabowska S, Schneider G,  
443 Kakar SS & Ratajczak MZ 2016 Vitamin D3 stimulates embryonic stem cells but inhibits  
444 migration and growth of ovarian cancer and teratocarcinoma cell lines. *J Ovarian Res* **9** 26.
- 445 Aleyasin A, Hosseini MA, Mahdavi A, Safdarian L, Fallahi P, Mohajeri MR, Abbasi M &  
446 Esfahani F 2011 Predictive value of the level of vitamin D in follicular fluid on the outcome of  
447 assisted reproductive technology. *European Journal of Obstetrics & Gynecology and*  
448 *Reproductive Biology* **159** 132-137.
- 449 Amegah AK, Klevor MK & Wagner CL 2017 Maternal vitamin D insufficiency and risk of  
450 adverse pregnancy and birth outcomes: A systematic review and meta-analysis of  
451 longitudinal studies. *PLoS One* **12** e0173605.
- 452 Andersen LB, Jorgensen JS, Jensen TK, Dalgard C, Barington T, Nielsen J, Beck-Nielsen  
453 SS, Husby S, Abrahamsen B, Lamont RF, et al. 2015 Vitamin D insufficiency is associated  
454 with increased risk of first-trimester miscarriage in the Odense Child Cohort. *Am J Clin Nutr*  
455 **102** 633-638.
- 456 Anifandis GM, Dafopoulos K, Messini CI, Chalvatzas N, Liakos N, Pournaras S & Messinis  
457 IE 2010 Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF  
458 outcome. *Reproductive Biology and Endocrinology* **8** 91.
- 459 Avila E, Diaz L, Barrera D, Halhali A, Mendez I, Gonzalez L, Zuegel U, Steinmeyer A &  
460 Larrea F 2007 Regulation of Vitamin D hydroxylases gene expression by 1,25-  
461 dihydroxyvitamin D3 and cyclic AMP in cultured human syncytiotrophoblasts. *J Steroid*  
462 *Biochem Mol Biol* **103** 90-96.
- 463 Bagot C, Troy P & Taylor H 2000 Alteration of maternal Hoxa10 expression by in vivo gene  
464 transfection affects implantation. *Gene therapy* **7** 1378.
- 465 Ball E, Bulmer JN, Ayis S, Lyall F & Robson SC 2006 Late sporadic miscarriage is  
466 associated with abnormalities in spiral artery transformation and trophoblast invasion. *J*  
467 *Pathol* **208** 535-542.
- 468 Bao BY, Yeh SD & Lee YF 2006 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell  
469 invasion via modulation of selective proteases. *Carcinogenesis* **27** 32-42.
- 470 Barrera D, Avila E, Hernandez G, Halhali A, Biruete B, Larrea F & Diaz L 2007 Estradiol and  
471 progesterone synthesis in human placenta is stimulated by calcitriol. *J Steroid Biochem Mol*  
472 *Biol* **103** 529-532.
- 473 Barrera D, Avila E, Hernandez G, Mendez I, Gonzalez L, Halhali A, Larrea F, Morales A &  
474 Diaz L 2008 Calcitriol affects hCG gene transcription in cultured human  
475 syncytiotrophoblasts. *Reprod Biol Endocrinol* **6** 3.
- 476 Bassir M, Laborie S, Lapillonne A, Claris O, Chappuis MC & Salle B 2001 Vitamin D  
477 deficiency in Iranian mothers and their neonates: a pilot study. *Acta paediatrica* **90** 577-579.

- 478 Belkacemi L, Zuegel U, Steinmeyer A, Dion JP & Lafond J 2005 Calbindin-D28k (CaBP28k)  
479 identification and regulation by 1,25-dihydroxyvitamin D3 in human choriocarcinoma cell line  
480 JEG-3. *Mol Cell Endocrinol* **236** 31-41.
- 481 Bodnar LM, Catov JM, Roberts JM & Simhan HN 2007a Prepregnancy obesity predicts poor  
482 vitamin D status in mothers and their neonates. *J Nutr* **137** 2437-2442.
- 483 Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW & Roberts JM 2007b Maternal  
484 vitamin D deficiency increases the risk of preeclampsia. *J Clin Endocrinol Metab* **92** 3517-  
485 3522.
- 486 Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, Marazita ML &  
487 Simhan HN 2010 Maternal serum 25-hydroxyvitamin D concentrations are associated with  
488 small-for-gestational age births in white women. *J Nutr* **140** 999-1006.
- 489 Bodnar LM, Krohn MA & Simhan HN 2009 Maternal vitamin D deficiency is associated with  
490 bacterial vaginosis in the first trimester of pregnancy. *The Journal of nutrition* **139** 1157-  
491 1161.
- 492 Bruns ME & Bruns DE 1983 Vitamin D metabolism and function during pregnancy and the  
493 neonatal period. *Ann Clin Lab Sci* **13** 521-530.
- 494 Bubanovic I 2004 1alpha,25-dihydroxy-vitamin-D3 as new immunotherapy in treatment of  
495 recurrent spontaneous abortion. *Med Hypotheses* **63** 250-253.
- 496 Camargo CA, Rifas-Shiman SL, Litonjua AA, Rich-Edwards JW, Weiss ST, Gold DR,  
497 Kleinman K & Gillman MW 2007 Maternal intake of vitamin D during pregnancy and risk of  
498 recurrent wheeze in children at 3 y of age. *The American Journal of Clinical Nutrition* **85** 788-  
499 795.
- 500 Caniggia I, Winter J, Lye SJ & Post M 2000 Oxygen and placental development during the  
501 first trimester: implications for the pathophysiology of pre-eclampsia. *Placenta* **21 Suppl A**  
502 S25-30.
- 503 Chan SY, Susarla R, Canovas D, Vasilopoulou E, Ohizua O, McCabe CJ, Hewison M &  
504 Kilby MD 2015 Vitamin D promotes human extravillous trophoblast invasion in vitro. *Placenta*  
505 **36** 403-409.
- 506 Chen JZ, Wong MH, Brennecke SP & Keogh RJ 2011 The effects of human chorionic  
507 gonadotrophin, progesterone and oestradiol on trophoblast function. *Mol Cell Endocrinol* **342**  
508 73-80.
- 509 Chen S, Zhu J, Zuo S, Ma J, Zhang J, Chen G, Wang X, Pan Y, Liu Y & Wang P 2015  
510 1,25(OH)2D3 attenuates TGF-beta1/beta2-induced increased migration and invasion via  
511 inhibiting epithelial-mesenchymal transition in colon cancer cells. *Biochem Biophys Res*  
512 *Commun* **468** 130-135.
- 513 Dawodu A, Agarwal M, Patel M & Ezimokhai M 1997 Serum 25-OHD and calcium  
514 homoeostasis in United Arab Emirates mothers and neonates: a preliminary report. *Middle*  
515 *East Paediatrics* **2** 9-11.
- 516 Denison FC, Roberts KA, Barr SM & Norman JE 2010 Obesity, pregnancy, inflammation,  
517 and vascular function. *Reproduction* **140** 373-385.

- 518 Diaz L, Noyola-Martinez N, Barrera D, Hernandez G, Avila E, Halhali A & Larrea F 2009  
519 Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. *J*  
520 *Reprod Immunol* **81** 17-24.
- 521 Diaz L, Sanchez I, Avila E, Halhali A, Vilchis F & Larrea F 2000 Identification of a 25-  
522 hydroxyvitamin D3 1alpha-hydroxylase gene transcription product in cultures of human  
523 syncytiotrophoblast cells. *J Clin Endocrinol Metab* **85** 2543-2549.
- 524 Du H, Daftary GS, Lalwani SI & Taylor HS 2005a Direct regulation of HOXA10 by 1,25-  
525 (OH)2D3 in human myelomonocytic cells and human endometrial stromal cells. *Mol*  
526 *Endocrinol* **19** 2222-2233.
- 527 Du H, Daftary GS, Lalwani SI & Taylor HS 2005b Direct regulation of HOXA10 by 1, 25-(OH)  
528 2D3 in human myelomonocytic cells and human endometrial stromal cells. *Molecular*  
529 *Endocrinology* **19** 2222-2233.
- 530 Eagleton C & Judkins A 2006 Vitamin D deficiency in pregnant New Zealand women. *The*  
531 *New Zealand Medical Journal (Online)* **119**.
- 532 Evans J 2016 Hyperglycosylated hCG: a Unique Human Implantation and Invasion Factor.  
533 *Am J Reprod Immunol* **75** 333-340.
- 534 Evans KN, Bulmer JN, Kilby MD & Hewison M 2004 Vitamin D and placental-decidual  
535 function. *J Soc Gynecol Investig* **11** 263-271.
- 536 Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD & Hewison M 2006 Effects of  
537 25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3 on Cytokine Production by Human  
538 Decidual Cells. *Biol Reprod*.
- 539 Fajol A, Honisch S, Zhang B, Schmidt S, Alkahtani S, Alarifi S, Lang F, Stournaras C &  
540 Foller M 2016 Fibroblast growth factor (Fgf) 23 gene transcription depends on actin  
541 cytoskeleton reorganization. *FEBS Lett* **590** 705-715.
- 542 Fischer KD & Agrawal DK 2014 Vitamin D regulating TGF-beta induced epithelial-  
543 mesenchymal transition. *Respir Res* **15** 146.
- 544 Goldman-Wohl D & Yagel S 2002 Regulation of trophoblast invasion: from normal  
545 implantation to pre-eclampsia. *Molecular and cellular endocrinology* **187** 233-238.
- 546 Gray TK, Lester GE & Lorenc RS 1979 Evidence for extra-renal 1 alpha-hydroxylation of 25-  
547 hydroxyvitamin D3 in pregnancy. *Science* **204** 1311-1313.
- 548 Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM & Adorini L 2001  
549 Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil  
550 treatment mediate transplantation tolerance. *J Immunol* **167** 1945-1953.
- 551 Gude NM, Roberts CT, Kalionis B & King RG 2004 Growth and function of the normal  
552 human placenta. *Thrombosis research* **114** 397-407.
- 553 Gui J, Rohrbach A, Borns K, Hillemanns P, Feng L, Hubel CA & von Versen-Hoynck F 2015  
554 Vitamin D rescues dysfunction of fetal endothelial colony forming cells from individuals with  
555 gestational diabetes. *Placenta* **36** 410-418.
- 556 Gysler SM, Mulla MJ, Stuhlman M, Sfakianaki AK, Paidas MJ, Stanwood NL, Garipey A,  
557 Brosens JJ, Chamley LW & Abrahams VM 2015 Vitamin D reverses aPL-induced

- 558 inflammation and LMWH-induced sFlt-1 release by human trophoblast. *Am J Reprod*  
559 *Immunol* **73** 242-250.
- 560 Halder SK, Osteen KG & Al-Hendy A 2013 Vitamin D3 inhibits expression and activities of  
561 matrix metalloproteinase-2 and -9 in human uterine fibroid cells. *Hum Reprod* **28** 2407-2416.
- 562 Halhali A, Acker GM & Garabedian M 1991 1,25-Dihydroxyvitamin D3 induces in vivo the  
563 decidualization of rat endometrial cells. *J Reprod Fertil* **91** 59-64.
- 564 Halhali A, Diaz L, Sanchez I, Garabedian M, Bourges H & Larrea F 1999 Effects of IGF-I on  
565 1,25-dihydroxyvitamin D(3) synthesis by human placenta in culture. *Mol Hum Reprod* **5** 771-  
566 776.
- 567 Halloran BP & DeLuca HF 1980 Effect of vitamin D deficiency on fertility and reproductive  
568 capacity in the female rat. *J Nutr* **110** 1573-1580.
- 569 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH  
570 & Weaver CM 2011a Evaluation, treatment, and prevention of vitamin D deficiency: an  
571 Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96** 1911-1930.
- 572 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad  
573 MH, Weaver CM & Endocrine S 2011b Evaluation, treatment, and prevention of vitamin D  
574 deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96**  
575 1911-1930.
- 576 Hou YF, Gao SH, Wang P, Zhang HM, Liu LZ, Ye MX, Zhou GM, Zhang ZL & Li BY 2016  
577 1 $\alpha$ ,25(OH)(2)D(3) Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through  
578 the Inhibition of Epithelial-Mesenchymal Transition. *Int J Mol Sci* **17**.
- 579 Javaid M, Crozier S, Harvey N, Gale C, Dennison E, Boucher B, Arden N, Godfrey K,  
580 Cooper C & Group PAHS 2006 Maternal vitamin D status during pregnancy and childhood  
581 bone mass at age 9 years: a longitudinal study. *The Lancet* **367** 36-43.
- 582 Johnson LE & DeLuca HF 2002 Reproductive defects are corrected in vitamin d-deficient  
583 female rats fed a high calcium, phosphorus and lactose diet. *J Nutr* **132** 2270-2273.
- 584 Jones G, Strugnelli SA & DeLuca HF 1998 Current understanding of the molecular actions of  
585 vitamin D. *Physiol Rev* **78** 1193-1231.
- 586 Kachkache M, Rebut-Bonneton C, Demignon J, Cynober E & Garabedian M 1993 Uterine  
587 cells other than stromal decidual cells are required for 1,25-dihydroxyvitamin D3 production  
588 during early human pregnancy. *FEBS Lett* **333** 83-88.
- 589 Kadyrov M, Kingdom JCP & Huppertz B 2006 Divergent trophoblast invasion and apoptosis  
590 in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-  
591 onset preeclampsia/intrauterine growth restriction. *American Journal of Obstetrics and*  
592 *Gynecology* **194** 557-563.
- 593 Karlsson T, Andersson L, Hussain A, Bosaeus M, Jansson N, Osmancevic A, Hulthen L,  
594 Holmang A & Larsson I 2015 Lower vitamin D status in obese compared with normal-weight  
595 women despite higher vitamin D intake in early pregnancy. *Clin Nutr* **34** 892-898.
- 596 Kaufmann P, Black S & Huppertz B 2003 Endovascular Trophoblast Invasion: Implications  
597 for the Pathogenesis of Intrauterine Growth Retardation and Preeclampsia. *Biology of*  
598 *Reproduction* **69** 1-7.

- 599 Keryer G, Alsat E, Tasken K & Evain-Brion D 1998 Cyclic AMP-dependent protein kinases  
600 and human trophoblast cell differentiation in vitro. *J Cell Sci* **111** ( Pt 7) 995-1004.
- 601 Khong TY 2008 The pathology of placenta accreta, a worldwide epidemic. *Journal of Clinical*  
602 *Pathology* **61** 1243.
- 603 Kovacs CS & Kronenberg HM 1997 Maternal-fetal calcium and bone metabolism during  
604 pregnancy, puerperium, and lactation. *Endocr Rev* **18** 832-872.
- 605 Krishnan AV, Swami S & Feldman D 2012 The potential therapeutic benefits of vitamin D in  
606 the treatment of estrogen receptor positive breast cancer. *Steroids* **77** 1107-1112.
- 607 Kwiecinski GG, Petrie GI & DeLuca HF 1989 1, 25-Dihydroxyvitamin D3 restores fertility of  
608 vitamin D-deficient female rats. *American Journal of Physiology-Endocrinology And*  
609 *Metabolism* **256** E483-E487.
- 610 Lewis S, Lucas RM, Halliday J & Ponsonby AL 2010 Vitamin D deficiency and pregnancy:  
611 from preconception to birth. *Mol Nutr Food Res* **54** 1092-1102.
- 612 Leyssens C, Verlinden L & Verstuyf A 2014 The future of vitamin D analogs. *Front Physiol* **5**  
613 122.
- 614 Liu N, Kaplan AT, Low J, Nguyen L, Liu GY, Equils O & Hewison M 2009 Vitamin D Induces  
615 Innate Antibacterial Responses in Human Trophoblasts via an Intracrine Pathway. *Biol*  
616 *Reprod* **80** 398-406.
- 617 Liu NQ & Hewison M 2012 Vitamin D, the placenta and pregnancy. *Arch Biochem Biophys*  
618 **523** 37-47.
- 619 Liu NQ, Kaplan AT, Lagishetty V, Ouyang YB, Ouyang Y, Simmons CF, Equils O & Hewison  
620 M 2011 Vitamin D and the regulation of placental inflammation. *J Immunol* **186** 5968-5974.
- 621 Ma Y, Johnson CS & Trump DL 2016 Mechanistic Insights of Vitamin D Anticancer Effects.  
622 *Vitam Horm* **100** 395-431.
- 623 Ma Y, Samaraweera M, Cooke-Hubley S, Kirby BJ, Karaplis AC, Lanske B & Kovacs CS  
624 2014 Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus  
625 homeostasis or prenatal skeletal development and mineralization. *Endocrinology* **155** 1596-  
626 1605.
- 627 Maghbooli Z, Hossein-nezhad A, Karimi F, Shafaei AR & Larijani B 2008 Correlation  
628 between vitamin D3 deficiency and insulin resistance in pregnancy. *Diabetes/metabolism*  
629 *research and reviews* **24** 27-32.
- 630 McGrath J 2001 Does 'imprinting' with low prenatal vitamin D contribute to the risk of various  
631 adult disorders? *Medical hypotheses* **56** 367-371.
- 632 Menkhorst E, Winship A, Van Sinderen M & Dimitriadis E 2016 Human extravillous  
633 trophoblast invasion: intrinsic and extrinsic regulation. *Reprod Fertil Dev* **28** 406-415.
- 634 Moller UK, Streym S, Heickendorff L, Mosekilde L & Rejnmark L 2012 Effects of 25OHD  
635 concentrations on chances of pregnancy and pregnancy outcomes: a cohort study in healthy  
636 Danish women. *Eur J Clin Nutr* **66** 862-868.

- 637 Moore JM, Nahlen BL, Misore A, Lal AA & Udhayakumar V 1999 Immunity to Placental  
638 Malaria. I. Elevated Production of Interferon- $\gamma$  by Placental Blood Mononuclear Cells Is  
639 Associated with Protection in an Area with High Transmission of Malaria. *J Infect Dis* **179**  
640 1218-1225.
- 641 Nguyen TP, Yong HE, Chollangi T, Borg AJ, Brennecke SP & Murthi P 2015 Placental  
642 vitamin D receptor expression is decreased in human idiopathic fetal growth restriction. *J*  
643 *Mol Med (Berl)* **93** 795-805.
- 644 Novakovic B, Sibson M, Ng HK, Manuelpillai U, Rakyan V, Down T, Beck S, Fournier T,  
645 Evain-Brion D, Dimitriadis E, et al. 2009 Placenta-specific methylation of the vitamin D 24-  
646 hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the  
647 fetomaternal interface. *J Biol Chem* **284** 14838-14848.
- 648 Noyola-Martinez N, Diaz L, Avila E, Halhali A, Larrea F & Barrera D 2013 Calcitriol  
649 downregulates TNF- $\alpha$  and IL-6 expression in cultured placental cells from preeclamptic  
650 women. *Cytokine* **61** 245-250.
- 651 Noyola-Martinez N, Diaz L, Zaga-Clavellina V, Avila E, Halhali A, Larrea F & Barrera D 2014  
652 Regulation of CYP27B1 and CYP24A1 gene expression by recombinant pro-inflammatory  
653 cytokines in cultured human trophoblasts. *J Steroid Biochem Mol Biol* **144 Pt A** 106-109.
- 654 Ohata Y, Yamazaki M, Kawai M, Tsugawa N, Tachikawa K, Koinuma T, Miyagawa K,  
655 Kimoto A, Nakayama M, Namba N, et al. 2014 Elevated fibroblast growth factor 23 exerts its  
656 effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice. *J Bone*  
657 *Miner Res* **29** 1627-1638.
- 658 Oreshkova T, Dimitrov R & Mourdjeva M 2012 A cross-talk of decidual stromal cells,  
659 trophoblast, and immune cells: a prerequisite for the success of pregnancy. *Am J Reprod*  
660 *Immunol* **68** 366-373.
- 661 Ota K, Dambaeva S, Kim MW, Han AR, Fukui A, Gilman-Sachs A, Beaman K & Kwak-Kim J  
662 2015 1,25-Dihydroxy-vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion, and  
663 degranulation in women with recurrent pregnancy losses. *Eur J Immunol* **45** 3188-3199.
- 664 Ozkan S, Jindal S, Greenseid K, Shu J, Zeitlian G, Hickmon C & Pal L 2010 Replete vitamin  
665 D stores predict reproductive success following in vitro fertilization. *Fertility and sterility* **94**  
666 1314-1319.
- 667 Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN & Goltzman D 2001  
668 Targeted ablation of the 25-hydroxyvitamin D 1 $\alpha$  -hydroxylase enzyme: evidence for  
669 skeletal, reproductive, and immune dysfunction. *Proc Natl Acad Sci U S A* **98** 7498-7503.
- 670 Pantham P, Aye ILMH & Powell TL 2015 Inflammation in Maternal Obesity and Gestational  
671 Diabetes Mellitus. *Placenta* **36** 709-715.
- 672 Piccinni MP, Scaletti C, Maggi E & Romagnani S 2000 Role of hormone-controlled Th1- and  
673 Th2-type cytokines in successful pregnancy. *J Neuroimmunol* **109** 30-33.
- 674 Pospeschova K, Rozehnal V, Stejskalova L, Vrzal R, Pospisilova N, Jamborova G, May K,  
675 Siegmund W, Dvorak Z, Nachtigal P, et al. 2009 Expression and activity of vitamin D  
676 receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines. *Mol Cell*  
677 *Endocrinol* **299** 178-187.

- 678 Reddy UM, Ko C-W & Willinger M 2006 Maternal age and the risk of stillbirth throughout  
679 pregnancy in the United States. *American Journal of Obstetrics and Gynecology* **195** 764-  
680 770.
- 681 Ringertz N 1970 Hydatidiform Mole, Invasive Mole and Choriocarcinoma in Sweden 1958-  
682 1965. *Acta Obstetricia et Gynecologica Scandinavica* **49** 195-203.
- 683 Rojansky N, Benshushan A, Meirsdorf S, Lewin A, Laufer N & Safran A 2000 Seasonal  
684 variability in fertilization and embryo quality rates in women undergoing IVF. *Fertility and*  
685 *sterility* **74** 476-481.
- 686 Rojansky N, Brzezinski A & Schenker JG 1992 Seasonality in human reproduction: an  
687 update. *Human Reproduction* **7** 735-745.
- 688 Rudge CV, Rollin HB, Nogueira CM, Thomassen Y, Rudge MC & Odland JO 2009 The  
689 placenta as a barrier for toxic and essential elements in paired maternal and cord blood  
690 samples of South African delivering women. *J Environ Monit* **11** 1322-1330.
- 691 Sachan A, Gupta R, Das V, Agarwal A, Awasthi PK & Bhatia V 2005 High prevalence of  
692 vitamin D deficiency among pregnant women and their newborns in northern India. *The*  
693 *American Journal of Clinical Nutrition* **81** 1060-1064.
- 694 Schneuer FJ, Roberts CL, Guilbert C, Simpson JM, Algert CS, Khambalia AZ, Tasevski V,  
695 Ashton AW, Morris JM & Nassar N 2014 Effects of maternal serum 25-hydroxyvitamin D  
696 concentrations in the first trimester on subsequent pregnancy outcomes in an Australian  
697 population. *Am J Clin Nutr* **99** 287-295.
- 698 Stephanou A, Ross R & Handwerger S 1994 Regulation of human placental lactogen  
699 expression by 1, 25-dihydroxyvitamin D3. *Endocrinology* **135** 2651-2656.
- 700 Tamblyn JA, Hewison M, Wagner CL, Bulmer JN & Kilby MD 2015 Immunological role of  
701 vitamin D at the maternal-fetal interface. *J Endocrinol* **224** R107-121.
- 702 Tamblyn JA, Susarla R, Jenkinson C, Jeffery LE, Ohizua O, Chun RF, Chan SY, Kilby MD &  
703 Hewison M 2017 Dysregulation of maternal and placental vitamin D metabolism in  
704 preeclampsia. *Placenta* **50** 70-77.
- 705 Tavakoli M, Jeddi-Tehrani M, Salek-Moghaddam A, Rajaei S, Mohammadzadeh A,  
706 Sheikhasani S, Kazemi-Sefat GE & Zarnani AH 2011 Effects of 1,25(OH)<sub>2</sub> vitamin D3 on  
707 cytokine production by endometrial cells of women with recurrent spontaneous abortion.  
708 *Fertil Steril* **96** 751-757.
- 709 Tavakoli M, Salek-Moghaddam A, Jeddi-Tehrani M, Talebi S, Kazemi-Sefat GE, Vafaei S,  
710 Mohammadzadeh A, Sheikhasani S & Zarnani AH 2015 Comparable vitamin D3  
711 metabolism in the endometrium of patients with recurrent spontaneous abortion and fertile  
712 controls. *Mol Reprod Dev* **82** 356-364.
- 713 Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E,  
714 Price CP & Boucher BJ 2002 Circulating MMP9, vitamin D and variation in the TIMP-1  
715 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?  
716 *QJM* **95** 787-796.
- 717 Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS & Hewison M 2005  
718 Biological actions of extra-renal 25-hydroxyvitamin D-1 $\alpha$ -hydroxylase and implications  
719 for chemoprevention and treatment. *J Steroid Biochem Mol Biol* **97** 103-109.



- 720 Tuan RS, Moore CJ, Brittingham JW, Kirwin JJ, Akins RE & Wong M 1991 In vitro study of  
721 placental trophoblast calcium uptake using JEG-3 human choriocarcinoma cells. *J Cell Sci*  
722 **98 ( Pt 3)** 333-342.
- 723 van der Meer IM, Karamali NS, Boeke AJP, Lips P, Middelkoop BJ, Verhoeven I & Wuister  
724 JD 2006 High prevalence of vitamin D deficiency in pregnant non-Western women in The  
725 Hague, Netherlands. *The American Journal of Clinical Nutrition* **84** 350-353.
- 726 Vigano P, Mangioni S, Pompei F & Chiodo I 2003 Maternal-conceptus cross talk—a review.  
727 *Placenta* **24** S56-S61.
- 728 von Versen-Hoyneck F, Brodowski L, Dechend R, Myerski AC & Hubel CA 2014 Vitamin D  
729 antagonizes negative effects of preeclampsia on fetal endothelial colony forming cell number  
730 and function. *PLoS One* **9** e98990.
- 731 Wagner CL & Greer FR 2008 Prevention of rickets and vitamin D deficiency in infants,  
732 children, and adolescents. *Pediatrics* **122** 1142-1152.
- 733 Wang LQ, Yan XT, Yan CF, Zhang XW, Hui LY, Xue M & Yu XW 2016 Women with  
734 Recurrent Miscarriage Have Decreased Expression of 25-Hydroxyvitamin D3-1alpha-  
735 Hydroxylase by the Fetal-Maternal Interface. *PLoS One* **11** e0165589.
- 736 Weisman Y, Harell A, Edelstein S, David M, Spirer Z & Golander A 1979 1 alpha, 25-  
737 Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua  
738 and placenta. *Nature* **281** 317-319.
- 739 Westwood MA-S, K; Finn-Sell, S; Tan, C; Cowley, E; Berneau, S; Adlam, D; Johnstone, E  
740 2017 Vitamin D Attenuates Sphingosine-1-Phosphate (S1P)-Mediated Inhibition of  
741 Extravillous Trophoblast Migration. *Placenta*.
- 742 Xu J, Jia X, Gu Y, Lewis DF, Gu X & Wang Y 2017 Vitamin D Reduces Oxidative Stress-  
743 Induced Procaspace-3/ROCK1 Activation and MP Release by Placental Trophoblasts. *J Clin*  
744 *Endocrinol Metab* **102** 2100-2110.
- 745 Yang K 1997 Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal  
746 glucocorticoids. *Reviews of Reproduction* **2** 129-132.
- 747 Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka  
748 K, Sato H, Uchiyama Y, et al. 1997 Mice lacking the vitamin D receptor exhibit impaired  
749 bone formation, uterine hypoplasia and growth retardation after weaning. *Nat Genet* **16** 391-  
750 396.
- 751 Zehnder D, Evans KN, Kilby MD, Bulmer JN, Innes BA, Stewart PM & Hewison M 2002 The  
752 ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and  
753 decidua. *Am J Pathol* **161** 105-114.
- 754 Zeng N, Salker MS, Zhang S, Singh Y, Shi B, Stournaras C & Lang F 2016  
755 1alpha,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by  
756 Targeting RAC1 and PAK1. *Cell Physiol Biochem* **40** 1455-1464.
- 757 Zhang C, Qiu C, Hu FB, David RM, Van Dam RM, Bralley A & Williams MA 2008 Maternal  
758 plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus.  
759 *PloS one* **3** e3753.

760

**Legend to figure**

**Figure 1. Vitamin D pathway components at the maternal-fetal interface associated with implantation.** Schematic showing key cell types involved in implantation and associated expression of components of the vitamin D system: vitamin D binding protein (DBP); vitamin D receptor (VDR); retinoid X receptor (RXR); vitamin D-25-hydroxylase (CYP2R1); 25-hydroxyvitamin D-1 $\alpha$ -hydroxylase (CYP27B1); vitamin D-24-hydroxylase (CYP24A1); human chorionic gonadotropin (hCG); human prolactin (hPL).

